{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:47Z","timestamp":1790289527042,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIHR Nottingham Digestive Diseases Biomedical Research Unit"},{"name":"NIHR Nottingham Biomedical Research Centre"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jhep.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T12:26:48Z","timestamp":1526905608000},"page":"948-957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications"],"prefix":"10.1016","volume":"69","author":[{"given":"Kalaiyarasi","family":"Kaliyaperumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane I.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Delahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.H.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Duckworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.05.013_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068111","article-title":"HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity","volume":"8","author":"Stephens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.05.013_b0010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B\u22171502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.05.013_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023371","article-title":"Large scale replication study of the association between HLA class II\/BTNL2 variants and osteoarthritis of the knee in European-descent populations","volume":"6","author":"Valdes","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.05.013_b0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s001250051328","article-title":"Genetic and immunological characteristics of Type I diabetes mellitus in an Indo-Aryan population","volume":"43","author":"Kelly","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2018.05.013_b0025","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.MIB.0000437567.12067.e7","article-title":"Ethnicity differences in genetic susceptibility to ulcerative colitis: a comparison of Indian asians and white northern Europeans","volume":"19","author":"Walker","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2018.05.013_b0030","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/hep.24299","article-title":"Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis","volume":"53","author":"Hov","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0035","unstructured":"DeLano WL. The PyMol Molecular Graphics System http:\/\/www.pymol.org, 2008."},{"key":"10.1016\/j.jhep.2018.05.013_b0040","doi-asserted-by":"crossref","first-page":"5.6.1","DOI":"10.1002\/0471250953.bi0506s47","article-title":"Comparative protein structure modeling using MODELLER","volume":"47","author":"Webb","year":"2014","journal-title":"Curr Protoc Bioinf"},{"key":"10.1016\/j.jhep.2018.05.013_b0045","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.181342398","article-title":"Electrostatics of nanosystems: application to microtubules and the ribosome","volume":"98","author":"Baker","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.jhep.2018.05.013_b0050","unstructured":"PDB2PQR. http:\/\/nbcr-222.ucsd.edu\/pdb2pqr_2.0.0\/."},{"key":"10.1016\/j.jhep.2018.05.013_b0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hep.1840080327","article-title":"Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases","volume":"8","author":"Stricker","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1399-6576.1985.tb02242.x","article-title":"HLA antigens in patients with unexplained hepatitis following halothane anesthesia","volume":"29","author":"Otsuka","year":"1985","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jhep.2018.05.013_b0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u22175701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.05.013_b0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bjornsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0075","unstructured":"http:\/\/livertox.nih.gov."},{"key":"10.1016\/j.jhep.2018.05.013_b0080","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0168-8278(00)80127-0","article-title":"Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions","volume":"33","author":"Aithal","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","article-title":"Comparison of two clinical scales for causality assessment in hepatotoxicity","volume":"33","author":"Lucena","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0090","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.05.013_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042418","article-title":"Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study","volume":"7","author":"M'Kada","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.05.013_b0100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0035-1567829","article-title":"Genome-wide association studies in drug-induced liver injury: step change in understanding the pathogenesis","volume":"35","author":"Aithal","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2018.05.013_b0105","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s11095-016-2091-1","article-title":"Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury?","volume":"34","author":"Daly","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.jhep.2018.05.013_b0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11901-017-0363-9","article-title":"Genetic factors influencing drug-induced liver injury: do they have a role in prevention and diagnosis?","volume":"16","author":"Clare","year":"2017","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jhep.2018.05.013_b0115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0120","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1023\/A:1005585515826","article-title":"HLA-A33\/B44\/DR6 is highly related to intrahepatic cholestasis induced by tiopronin","volume":"45","author":"Kurosaki","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2018.05.013_b0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","article-title":"Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study","volume":"8","author":"Hirata","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2018.05.013_b0135","first-page":"769","article-title":"Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?","volume":"13","author":"Pariente","year":"1989","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2018.05.013_b0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: clinical characterization and identification of HLA-B \u221735:02 as a risk factor","volume":"67","author":"Urban","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0145","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B\u22175701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2018.05.013_b0150","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B\u221757:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2018.05.013_b0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2017.00090","article-title":"HLA-B\u221757 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians","volume":"8","author":"Petros","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2018.05.013_b0160","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/QAI.0b013e31827ca50f","article-title":"Associations between HLA-DRB1\u22170102, HLA-B\u22175801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa","volume":"62","author":"Phillips","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2018.05.013_b0165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2018.05.013_b0170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate\u2013induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","article-title":"Co-amoxiclav jaundice: clinical and histological features and HLA class II association","volume":"47","author":"O'Donohue","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.05.013_b0180","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2010.05.033","article-title":"Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury","volume":"53","author":"Donaldson","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0185","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2018.05.013_b0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2018.05.013_b0195","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1\u221702:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.05.013_b0200","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.2013.52.9867","article-title":"Prospective validation of HLA-DRB1\u221707:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury","volume":"32","author":"Schaid","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.05.013_b0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/tpj.2015.40","article-title":"Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01","volume":"16","author":"Parham","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2018.05.013_b0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs","volume":"7","author":"Aithal","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0215","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2018.05.013_b0220","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/FPC.0000000000000209","article-title":"HLA-DRB1\u221716: 01-DQB1\u221705: 02 is a novel genetic risk factor for flupirtine-induced liver injury","volume":"26","author":"Nicoletti","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2018.05.013_b0225","first-page":"1","article-title":"Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to anti-tuberculosis drug-induced liver injury (ATDILI)","volume":"66","author":"Nicoletti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0230","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.05.013_b0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2133\/dmpk.25.298","article-title":"Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese","volume":"25","author":"Ariyoshi","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jhep.2018.05.013_b0245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00228-014-1703-0","article-title":"N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group","volume":"70","author":"Ng","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2018.05.013_b0250","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/FPC.0b013e3283589a76","article-title":"Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs","volume":"22","author":"Urban","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2018.05.013_b0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.tpj.6500123","article-title":"Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity","volume":"2","author":"Acuna","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2018.05.013_b0260","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/01.wnl.0000187066.81162.70","article-title":"Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism","volume":"65","author":"Martignoni","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2018.05.013_b0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/omi.2017.0019","article-title":"Genome-wide association and replication study of hepatotoxicity induced by antiretrovirals alone or with concomitant anti-tuberculosis drugs","volume":"21","author":"Petros","year":"2017","journal-title":"OMICS"},{"key":"10.1016\/j.jhep.2018.05.013_b0270","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12864-016-3078-3","article-title":"Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity","volume":"17","author":"Petros","year":"2016","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jhep.2018.05.013_b0275","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/liv.12216","article-title":"Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1\/ABCB11 mutations?","volume":"33","author":"El Sherrif","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.05.013_b0280","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2010.08.002","article-title":"Drug-induced liver injury: is it time for genetics to change our clinical practice?","volume":"53","author":"Invernizzi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0285","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2018.05.013_b0290","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0295","first-page":"971","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0300","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13724","article-title":"Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK","author":"Gordon","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.05.013_b0305","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0310","first-page":"1159","article-title":"Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre","volume":"25","author":"Donaghy","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0315","first-page":"914","article-title":"The distribution of antinuclear antibody titers in \u201cnormal\u201d children and adults","volume":"26","author":"Craig","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0320","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2010\/431913","article-title":"Autoantibodies and liver disease: uses and abuses","volume":"24","author":"Zeman","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.05.013_b0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Gonzalez-Quintela","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2018.05.013_b0330","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0335","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0340","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0345","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.18632\/oncotarget.4400","article-title":"A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications","volume":"6","author":"Weng","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2018.05.013_b0350","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0360","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkx183","article-title":"Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study","volume":"72","author":"Wing","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2018.05.013_b0365","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0370","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcma.2015.12.006","article-title":"Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: Systematic review and meta-analysis","volume":"79","author":"Wang","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jhep.2018.05.013_b0375","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2017.215","article-title":"Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians","volume":"112","author":"Chalasani","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.05.013_b0380","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cbi.2010.09.011","article-title":"Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity","volume":"192","author":"Park","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jhep.2018.05.013_b0385","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.20205","article-title":"Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity","volume":"39","author":"Aithal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0390","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.114.215079","article-title":"Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients","volume":"350","author":"Hammond","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2018.05.013_b0395","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/17425255.2015.992414","article-title":"Human leukocyte antigen genetic risk factors of drug-induced liver toxicology","volume":"11","author":"Grove","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jhep.2018.05.013_b0400","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B\u221757:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0405","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/hep.27912","article-title":"Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury","volume":"62","author":"Kim","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsi.2013.09.005","article-title":"Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide","volume":"31","author":"Pichler","year":"2013","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jhep.2018.05.013_b0415","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jhep.2018.05.013_b0420","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2018.05.013_b0425","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.05.013_b0430","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/jcm4051063","article-title":"MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury","volume":"4","author":"McGill","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2018.05.013_b0435","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","article-title":"High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial","volume":"64","author":"Larsen","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0445","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.013_b0450","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2014.11.020","article-title":"24-Nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis","volume":"62","author":"Sombetzki","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0455","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2015-309528","article-title":"Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury","volume":"65","author":"Benesic","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.05.013_b0460","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/labinvest.2012.64","article-title":"Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies","volume":"92","author":"Benesic","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2018.05.013_b0465","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0470","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yrtph.2009.03.003","article-title":"Drug-induced liver injury following positive drug rechallenge","volume":"54","author":"Papay","year":"2009","journal-title":"Regul Toxicol Pharm"},{"key":"10.1016\/j.jhep.2018.05.013_b0475","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14740330903397378","article-title":"Rechallenge in drug-induced liver injury: the attractive hazard","volume":"8","author":"Andrade","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhep.2018.05.013_b0480","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2018.05.013_b0485","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000322298","article-title":"Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury","volume":"84","author":"Wree","year":"2011","journal-title":"Digestion"},{"key":"10.1016\/j.jhep.2018.05.013_b0495","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.26678","article-title":"Steroid use in acute liver failure","volume":"59","author":"Karkhanis","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.013_b0500","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bjornsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.013_b0505","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3748\/wjg.v16.i8.934","article-title":"Difficult treatment decisions in autoimmune hepatitis","volume":"16","author":"Czaja","year":"2010","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T18:01:12Z","timestamp":1560362472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818320592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0168827818320592"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}